Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
نویسندگان
چکیده
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
منابع مشابه
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
patient data meta-analysis. Eur Respir J 2013; 42: 169–179. 9 Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1. 10 Matteelli A, D’Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015; 15: 1131–1132. 11 World Health Organization. The use of delamanid...
متن کاملVariation in policy and practice of adolescent tuberculosis management in the WHO European Region
in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...
متن کاملCompassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
BACKGROUND Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. METHODS We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 and July 2013 a...
متن کاملBedaquiline versus placebo for management of multidrug-resistant tuberculosis: A systematic review
Sir, Charan et al. compared time to conversion of positive sputum to negative and mortality between bedaquiline and placebo. In all the forest plots as heterogenicity, I2 = 0% or nonsignificant, they should have pooled data under fixed‐effect model rather than using random effect model. We have certain observations that need clarifications. Authors’ conclusion with regard to increased mortality...
متن کاملCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline use...
متن کامل